Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study

Table 1 Basic characteristics of IP versus IM in the treatment of LM

Factor	IP	IM	All patients	P
No. of patients	34	7	41
Age				0.923
<60	23	4	27(65.9%)
≥60	11	3	14(34.1%)
Sex				1.000
Male	14	3	17(41.5%)
Female	20	4	24(58.5%)
ECOG PS				0.302
< 2	17	2	19(46.3%)
≥2	17	5	22(53.7%)
CSF				0.376
Negative	0	0	0
Positive	33	7	40(97.6%)
Unknown	0	1	1(2.4%)
MRI				0.299
Negative	9	0	9(22%)
Positive	25	7	32(78%)
Brain metastasis				0.299
Present	25	7	32(78%)
Absent	9	0	9(22%)
Systemic therapy before IC				0.372
1st/2nd-generation TKIs	22	2	24(58.5%)
3rd-generation TKIs	18	3	21(51.2%)
Chemotherapy	6	5	11(26.8%)
Bevacizumab before IC				0.958
Yes	6	3	9(22%)
No	28	4	32(78%)
Gene mutation				0.334
EGFR	27	4	31(75.6%)
MET	1	0	1(2.4%)
None	7	3	10(24.4%)

ECOG, Eastern Cooperative Oncology Group; PS, performance status; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; EGFR, epidermal growth factor receptor; MET, mesenchymal-to-epithelial transition

ISSN: 1471-2407